Effects of COVID-19 in patients with hematologic cancer

Study of the effects of COVID-19 in patients with hematologic cancer during the first month of the pandemic that analyzes whether these patients have a higher risk of becoming infected than the rest of the population

Description of the Study:

  • Title: The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting.
  • Principal Investigators: Maria Condom, Alberto Mussetti, Clara Maluquer, Rocío Parody, Eva González‐Barca, Montserrat Arnan, Adaia Albasanz‐Puig, Helena Pomares, Maria Queralt Salas, Itziar Carro, Marta Peña, Victòria Clapes, Cristina Baca Cano, Ana Carla Oliveira Ramos, Gabriela Sanz‐Linares, Gabriel Moreno‐González, Santiago Mercadal, Concepcion Boqué, Carlota Gudiol, Eva Domingo‐Domènech and Anna Sureda.
  • Centers of Implementation: Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) and Institut Català d’Oncologia (ICO) – Hospital Duran i Reynals.
  • Study Population: All patients were ≥18 years old and had an onco‐hematological malignancy.
  • Study Type: Retrospective study.
  • Design: Clinical data from patients was collected between March 13, 2020 (the first day of government‐imposed restrictions related to COVID‐19 in Spain) and April 12, 2020 via a retrospective chart review.
  • Methods: COVID‐19 diagnosis and response were confirmed in accordance with World Health Organization criteria. Hematological disease type and status were defined per international standard criteria. In the second part of the study, the indirect effects of COVID‐19 on inpatient and outpatient activity of their department were described. Clinical and logistic data from both types of activity were compared with average values calculated from the prior 3 months (between December 13, 2019, and March 12, 2020).

Objectives of the Study:

Principal Objectives:
(1) To describe the characteristics and outcomes of a consecutive cohort of 24 onco‐hematological patients with COVID‐19 during the first month of the pandemic.

(2) To describe variations in healthcare resource utilization within our hematology department.

More about this Study:

Scientific context: The novel coronavirus SARS‐CoV-2 recently emerged as a global threat. High hospitalization (around 20% of diagnosed cases) and mortality rates (2%‐3%) of patients with COVID‐19 have led to an unprecedented burden on healthcare systems. Indeed, the impact of COVID‐19 has even prevented healthcare professionals from continuing normal utilization practices of healthcare resources for all other health matters unrelated to the pandemic. Evidence of such can be seen in emergency departments and other vital services such as onco‐hematology departments.

IDIBELL: It is a biomedical research center created in 2004. It is participated by Hospital Universitari de Bellvitge and Hospital de Viladecans de l’Institut Català de la Salut, Institut Català d’Oncologia, Universitat de Barcelona and Ajuntament de l’Hospitalet de Llobregat.

ICO: It is a public monographic center on cancer created in 1995 by Departament de Salut de la Generalitat de Catalunya. It deals with the disease in an integral way since it brings together, within the same organization, prevention, assistance, specialized training and research.


Other Studies about Oncology:


Rejoignez l’étude COVonco et contribuez a comprendre mieux l’impact de la COVID-19 dans l’oncologie.